We are advancing a pipeline of small-molecule therapeutics with the goal of bringing new precision neuromedicines to patients living with cognitive deficits associated with CNS disorders, including major psychiatric and neurodegenerative disorders such as depression, Alzheimer’s disease, and schizophrenia.

DPX-101 is a Precision-Targeted α5-GABA-A PAM
DPX-101 is a receptor-positive allosteric modulator (PAM) that targets the α5 subunit-containing GABA-A receptor to augment its function to restore contacts between neurons.

DPX-101 is unique in its subtype specificity, and we expect its highly targeted mechanism to sustain efficacy while minimizing many of the risks and side effects associated with α1-selective modulators of GABA-A, positioning DPX-101 as a best-in-class molecule targeting the α5-GABA-A receptor.

In gold-standard preclinical models of major depressive disorder, DPX-101 augmented the function of the α5-GABA-A receptor to produce robust pro-cognitive, antidepressant, and brain-protective effects. These findings provide the basis for our plans to initiate a Phase 1 clinical study to evaluate the safety, tolerability, and pharmacokinetics of DPX-101 in humans.

Our Initial Focus: Major Depressive Disorder
An estimated 11.2 million Major Depressive Disorder (MDD) patients in the U.S. suffer from cognitive impairment. Cognitive impairment is a core symptom of MDD that affects many areas of cognition, including learning and memory, executive functioning, processing speed, and attention and concentration. Cognitive impairment occurs during and between episodes of MDD, contributing significantly to occupational and functional disability and impacting quality of life.